SI2200610T1 - Co-administration of pimavanserin with other agents - Google Patents
Co-administration of pimavanserin with other agents Download PDFInfo
- Publication number
- SI2200610T1 SI2200610T1 SI200831943T SI200831943T SI2200610T1 SI 2200610 T1 SI2200610 T1 SI 2200610T1 SI 200831943 T SI200831943 T SI 200831943T SI 200831943 T SI200831943 T SI 200831943T SI 2200610 T1 SI2200610 T1 SI 2200610T1
- Authority
- SI
- Slovenia
- Prior art keywords
- disorder
- composition
- disease
- group
- psychosis
- Prior art date
Links
- RKEWSXXUOLRFBX-UHFFFAOYSA-N pimavanserin Chemical compound C1=CC(OCC(C)C)=CC=C1CNC(=O)N(C1CCN(C)CC1)CC1=CC=C(F)C=C1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 title claims abstract 5
- 229960003300 pimavanserin Drugs 0.000 title claims abstract 5
- 238000011260 co-administration Methods 0.000 title claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 11
- 239000000203 mixture Substances 0.000 claims abstract 11
- 230000005856 abnormality Effects 0.000 claims abstract 8
- 230000001713 cholinergic effect Effects 0.000 claims abstract 8
- 201000010099 disease Diseases 0.000 claims abstract 6
- 208000028017 Psychotic disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 5
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 4
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 3
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000018300 basal ganglia disease Diseases 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 229960003530 donepezil Drugs 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 229960001685 tacrine Drugs 0.000 claims 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims 2
- 206010001488 Aggression Diseases 0.000 claims 1
- 206010001540 Akathisia Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006100 Bradykinesia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000012239 Developmental disease Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000004547 Hallucinations Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000006083 Hypokinesia Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010033664 Panic attack Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 208000012545 Psychophysiologic disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010040108 Serotonin syndrome Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 206010042458 Suicidal ideation Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940095064 tartrate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97442607P | 2007-09-21 | 2007-09-21 | |
| US98625007P | 2007-11-07 | 2007-11-07 | |
| US5097608P | 2008-05-06 | 2008-05-06 | |
| PCT/US2008/077139 WO2009039460A2 (en) | 2007-09-21 | 2008-09-19 | Co-administration of pimavanserin with other agents |
| EP08831500.7A EP2200610B1 (en) | 2007-09-21 | 2008-09-19 | Co-administration of pimavanserin with other agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2200610T1 true SI2200610T1 (en) | 2018-06-29 |
Family
ID=40350231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831943T SI2200610T1 (en) | 2007-09-21 | 2008-09-19 | Co-administration of pimavanserin with other agents |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20090082388A1 (enExample) |
| EP (1) | EP2200610B1 (enExample) |
| JP (1) | JP2010540454A (enExample) |
| AU (1) | AU2008302079A1 (enExample) |
| CA (1) | CA2700331A1 (enExample) |
| DK (1) | DK2200610T3 (enExample) |
| HU (1) | HUE037639T2 (enExample) |
| NO (1) | NO2200610T3 (enExample) |
| SI (1) | SI2200610T1 (enExample) |
| WO (1) | WO2009039460A2 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2190844B3 (en) | 2007-08-15 | 2013-07-17 | Arena Pharmaceuticals, Inc. | Imidazo[1,2-a]pyridine derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
| RS57110B1 (sr) | 2008-10-28 | 2018-06-29 | Arena Pharm Inc | Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim |
| DK3061821T3 (da) | 2009-07-22 | 2019-08-26 | PureTech Health LLC | Sammensætninger til behandling af forstyrrelser lindret af muskarinreceptoraktivering |
| US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
| WO2011103448A1 (en) * | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Methods and compositions for treating psychotic disorders using antipsychotic combination therapy |
| US10583138B2 (en) | 2012-07-12 | 2020-03-10 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2012113103A1 (en) * | 2011-02-25 | 2012-08-30 | Helsinn Healthcare S.A. | Asymmetric ureas and medical uses thereof |
| CA2850707C (en) | 2011-10-03 | 2023-03-21 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| WO2014085362A1 (en) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
| TWI690512B (zh) * | 2014-03-07 | 2020-04-11 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
| US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
| CN106536508B (zh) | 2014-04-23 | 2019-08-09 | 武田药品工业株式会社 | 用于治疗阿尔茨海默病的具有胆碱能毒蕈碱m1受体正变构调节剂活性的化合物 |
| US9592239B2 (en) | 2014-09-12 | 2017-03-14 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
| EP3285800B1 (en) * | 2015-04-24 | 2019-09-18 | Consiglio Nazionale Delle Ricerche | A new therapeutic use of the botulinum neurotoxin serotype a |
| JP6527290B2 (ja) * | 2015-05-18 | 2019-06-05 | 重慶潤澤医薬有限公司 | 製薬領域における右旋性オキシラセタムの応用 |
| AU2016276966A1 (en) | 2015-06-12 | 2018-01-18 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder |
| CR20170568A (es) | 2015-06-26 | 2018-04-20 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| EP3322415A4 (en) | 2015-07-15 | 2019-03-13 | Axovant Sciences GmbH | DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR FOR PROPHYLAXIS AND TREATMENT OF HALLUCINATIONS RELATED TO A NEUROGENERATIVE DISEASE |
| CN107848972B (zh) | 2015-07-20 | 2021-06-18 | 阿卡蒂亚药品公司 | 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法 |
| JP6787913B2 (ja) | 2015-10-20 | 2020-11-18 | 武田薬品工業株式会社 | 複素環化合物 |
| CN105929030B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种哌马色林中有机杂质的检测方法 |
| CN105481757A (zh) * | 2015-12-25 | 2016-04-13 | 北京康立生医药技术开发有限公司 | 一种哌马色林的制备方法 |
| CN106943344B (zh) * | 2016-02-25 | 2018-12-14 | 重庆润泽医药有限公司 | 一种稳定性好的(s)-4-羟基-2氧代-1-吡咯烷乙酰胺注射剂及其制备方法 |
| CN106943345A (zh) * | 2016-02-25 | 2017-07-14 | 重庆润泽医药有限公司 | 一种注射用的左旋奥拉西坦及其制备方法 |
| LT3390355T (lt) | 2016-03-22 | 2023-03-10 | Helsinn Healthcare S.A. | Benzensulfonil-asimetriniai karbamidai ir jų medicininis panaudojimas |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017172757A1 (en) * | 2016-03-29 | 2017-10-05 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
| US20190117636A1 (en) * | 2016-03-29 | 2019-04-25 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
| CN106943361A (zh) * | 2016-03-31 | 2017-07-14 | 重庆润泽医药有限公司 | 一种（s）-4-羟基-2氧代-1-吡咯烷乙酰胺无菌粉末及其制备方法 |
| CN106943360A (zh) * | 2016-03-31 | 2017-07-14 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦无菌粉末及其制备方法 |
| CN107303269A (zh) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | 一种左旋奥拉西坦注射液的制备方法 |
| CN107303270A (zh) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | 一种稳定抗氧化的(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺注射液 |
| CN107303268A (zh) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | 稳定抗氧化的左旋奥拉西坦注射液的制备方法 |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| RS67273B1 (sr) * | 2017-08-21 | 2025-10-31 | Acadia Pharm Inc | Jedinjenja, njihove soli i njihova upotreba u lečenju bolesti |
| EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
| PL3505157T3 (pl) | 2017-12-29 | 2022-04-11 | Celon Pharma S.A. | Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie |
| IL295341B2 (en) | 2018-09-28 | 2025-01-01 | Karuna Therapeutics Inc | Compositions and methods for treating diseases improved by activating muscarinic receptors |
| WO2020092618A1 (en) * | 2018-10-30 | 2020-05-07 | Acadia Pharmaceuticals Inc. | Methods of treating depression, anxiety and sexual dysfunction using the compound primavanserin |
| CN109633026A (zh) * | 2019-01-03 | 2019-04-16 | 上海市农业科学院 | 一种液相色谱-串联质谱检测多菌灵及其代谢物的方法 |
| CN113214231B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其医疗应用 |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| CA3209262A1 (en) * | 2021-02-24 | 2022-09-01 | Andrew Miller | Methods for treating disorders ameliorated by muscarinic receptor activation |
| US20240139169A1 (en) * | 2021-02-26 | 2024-05-02 | Bioxcel Therapeutics, Inc. | Methods and compositions for treating agitation |
| US20220370382A1 (en) * | 2021-05-21 | 2022-11-24 | Diana Driscoll | Methods and compositions for correction of autonomic dysfunctions |
| WO2022265878A1 (en) * | 2021-06-14 | 2022-12-22 | Mind Medicine, Inc. | Controlling effects after 5ht2a agonists administration |
| WO2024112941A1 (en) * | 2022-11-22 | 2024-05-30 | GATC Health Corp | Butyrylcholinesterase (buche) lateral flow assay (lfa) for determining elevated risk of sids |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1507462A (en) * | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
| US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
| US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
| US4332804A (en) * | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
| FR2642069B1 (fr) * | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5214055A (en) * | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
| US5216165A (en) * | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
| US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
| US5707798A (en) * | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
| DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| WO1997020552A1 (en) * | 1995-12-07 | 1997-06-12 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors |
| US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| WO1999052927A1 (en) * | 1998-04-14 | 1999-10-21 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| GB9816263D0 (en) * | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6358698B1 (en) * | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
| US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| US20050148018A1 (en) * | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
| FR2802206B1 (fr) * | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| MXPA02008770A (es) * | 2000-03-06 | 2004-09-10 | Acadia Pharm Inc | Compuestos azaciclicos para uso en el tratamiento de enfermedades relacionadas con la serotonina. |
| GB0011838D0 (en) * | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| DE60141752D1 (de) * | 2000-06-30 | 2010-05-20 | Innogenetics Nv | Differentielle diagnose von neurologischen krankheiten |
| US20020156068A1 (en) * | 2001-03-22 | 2002-10-24 | Behan Dominic P. | Anti-psychosis combination |
| MXPA04006280A (es) * | 2001-12-28 | 2004-09-27 | Acadia Pharm Inc | Compuestos espiroazaciclicos como moduladores de receptor de monoamina. |
| US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| MXPA04012893A (es) * | 2002-06-24 | 2005-03-31 | Acadia Pharm Inc | Derivados de piperidina n-substituidos como agentes receptores de serotonina. |
| US7601740B2 (en) * | 2003-01-16 | 2009-10-13 | Acadia Pharmaceuticals, Inc. | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases |
| EP1576985A1 (en) * | 2004-03-18 | 2005-09-21 | B&B Beheer NV | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
| US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| CN102153505B (zh) * | 2004-09-27 | 2014-10-22 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐的合成和晶形 |
-
2008
- 2008-09-19 NO NO08831500A patent/NO2200610T3/no unknown
- 2008-09-19 SI SI200831943T patent/SI2200610T1/en unknown
- 2008-09-19 JP JP2010526035A patent/JP2010540454A/ja not_active Withdrawn
- 2008-09-19 AU AU2008302079A patent/AU2008302079A1/en not_active Abandoned
- 2008-09-19 CA CA2700331A patent/CA2700331A1/en not_active Abandoned
- 2008-09-19 WO PCT/US2008/077139 patent/WO2009039460A2/en not_active Ceased
- 2008-09-19 HU HUE08831500A patent/HUE037639T2/hu unknown
- 2008-09-19 DK DK08831500.7T patent/DK2200610T3/en active
- 2008-09-19 EP EP08831500.7A patent/EP2200610B1/en active Active
- 2008-09-19 US US12/234,573 patent/US20090082388A1/en not_active Abandoned
-
2014
- 2014-05-28 US US14/289,450 patent/US20140349976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010540454A (ja) | 2010-12-24 |
| US20140349976A1 (en) | 2014-11-27 |
| DK2200610T3 (en) | 2018-04-23 |
| NO2200610T3 (enExample) | 2018-06-09 |
| EP2200610B1 (en) | 2018-01-10 |
| HUE037639T2 (hu) | 2018-09-28 |
| WO2009039460A3 (en) | 2009-11-26 |
| CA2700331A1 (en) | 2009-03-26 |
| WO2009039460A2 (en) | 2009-03-26 |
| AU2008302079A1 (en) | 2009-03-26 |
| EP2200610A2 (en) | 2010-06-30 |
| US20090082388A1 (en) | 2009-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2200610T1 (en) | Co-administration of pimavanserin with other agents | |
| NZ589813A (en) | Azaadamantane derivatives and their uses as nicotinic acetylcholine receptor ligands | |
| MX2010008700A (es) | Moduladores de beta-amiloide. | |
| WO2009046841A3 (de) | Piperidin- und piperazinderivate zur behandlung von tumoren | |
| MY156254A (en) | Salts and polymorphs of a tetracycline compound | |
| AT516600A5 (de) | Herstellung von faktor h (fh) und fh-derivaten aus plasma | |
| MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
| IN2012DN02763A (enExample) | ||
| BR112012012947A2 (pt) | forma cristalina e amorfa de hemitartarato genz 112638 como inibidor de glicosilceramida sintase | |
| NZ631601A (en) | Solid forms of a thiophosphoramidate nucleotide prodrug | |
| MX2010009854A (es) | Agente para liberacion de sustancia funcional. | |
| MX2009007630A (es) | Derivados de tiazolidina y metodos para su preparacion. | |
| WO2007089703A3 (en) | Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same | |
| CL2009000879A1 (es) | Metodo para fabricar un producto en un biorreactor que comprende cultivar microorganismos que son adaptados o mutagenizados para que exhiban por lo menos un 150% de tolerancia al producto; sistema para fabricar un producto; biorreactor. | |
| MX2009010223A (es) | Antagonistas del receptor de adenosina a2a. | |
| BR112012022910A2 (pt) | inibidores de pde10 e composições e métodos relacionados | |
| MX2009007713A (es) | Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas. | |
| EP2760858A4 (en) | URIDEINDIPHOSPHATE DERIVATIVES, COMPOSITIONS THEREFOR AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER | |
| PA8855001A1 (es) | Monocarbamas | |
| MX2009011749A (es) | Compuestos triciclicos como inhibidores de metaloproteinasa matricial. | |
| WO2009153178A3 (en) | Aryl ketone as mri | |
| DE602006008314D1 (de) | Nach dem elektrotauchverfahren auftragbare wässrige harzdispersion und verfahren zu ihrer herstellung | |
| IL200029A0 (en) | Methods for the treatment of senile dementia of the alzheimer's type | |
| ATE524469T1 (de) | Alkinylarylverbindungen und salze davon, diese enthaltende pharmazeutische zusammensetzungen, verfahren zu deren herstellung und deren verwendungen | |
| WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer |